Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Globe Newswire•15/10/2026•07:00 ET
0
Key Highlights
- ➤SER-428 cut Enterococcus faecium and Klebsiella pneumoniae abundance up to 1,000-fold
- ➤SER-428 liquid formulation remained stable through simulated feeding tube delivery
- ➤Seres plans Phase 1b MICU trial with Columbia University’s Daniel E. Freedberg
- ➤SER-428 clinical development depends on grants or other funding
- ➤SER-155 Phase 1b showed 77% relative risk reduction in bloodstream infections
Expert Statements
Matthew Henn, President and Chief Scientific Officer of Seres Therapeutics
“Patients admitted to the medical intensive care unit with sepsis remain at high risk for subsequent serious infections, particularly after antibiotic exposure disrupts the gastrointestinal microbiome and allows pathogenic bacteria to proliferate”
Matthew Henn, President and Chief Scientific Officer of Seres Therapeutics
“SER-428 builds on our positive clinical experience with SER-155 and is designed specifically with the needs of critically ill patients in mind.”
Matthew Henn, President and Chief Scientific Officer of Seres Therapeutics
“The findings presented at IDWeek provide important preclinical support for both the biological activity and the formulation characteristics of SER-428 as we advance the clinical development plans for the program.”
Matthew Henn, President and Chief Scientific Officer of Seres Therapeutics
“We appreciate the long-standing support from CARB-X, which has allowed this work to progress.”
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models
Get started
Create a free account to read the full story.